Last reviewed · How we verify
Infusion with paracetamol
Paracetamol inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.
Paracetamol inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever. Used for Acute pain management, Fever reduction.
At a glance
| Generic name | Infusion with paracetamol |
|---|---|
| Also known as | paracetamol=acetaminophen |
| Sponsor | University of Helsinki |
| Drug class | Analgesic and antipyretic |
| Target | Cyclooxygenase (COX) enzymes |
| Modality | Small molecule |
| Therapeutic area | Pain management, Fever reduction |
| Phase | FDA-approved |
Mechanism of action
Paracetamol (acetaminophen) works primarily through inhibition of cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing prostaglandin production. This leads to decreased pain signal transmission and lowering of the hypothalamic temperature set point. The intravenous infusion formulation provides rapid systemic delivery for acute pain and fever management.
Approved indications
- Acute pain management
- Fever reduction
Common side effects
- Hepatotoxicity (at overdose)
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (PHASE3)
- Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infusion with paracetamol CI brief — competitive landscape report
- Infusion with paracetamol updates RSS · CI watch RSS
- University of Helsinki portfolio CI